Brief: Karolinska Development's Portfolio Company Umecrine Cognition Raises MSEK 24.6 For The Ongoing Clinical Development Of Golexanolone
14/07/2025 16:05
July 14 (Reuters) - Karolinska Development AB KDEV.ST: REG-KAROLINSKA DEVELOPMENT’S PORTFOLIO COMPANY UMECRINE COGNITION RAISES MSEK 24.6 FOR THE ONGOING CLINICAL DEVELOPMENT OF GOLEXANOLONE Source text: ID:nGNE4c9C9q Further company coverage: KDEV.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kdventures AB
See all newsRefile: BRIEF-Umecrine Cognition Gets Notice Of Allowance In US
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue